Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Cash & Equivalents (2020 - 2025)

RxSight (RXST) has disclosed Cash & Equivalents for 6 consecutive years, with $19.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 91.59% year-over-year to $19.9 million, compared with a TTM value of $19.9 million through Dec 2025, down 91.59%, and an annual FY2025 reading of $19.9 million, down 91.59% over the prior year.
  • Cash & Equivalents was $19.9 million for Q4 2025 at RxSight, down from $40.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $237.2 million in Q4 2024 and bottomed at $8.8 million in Q2 2023.
  • Average Cash & Equivalents over 5 years is $105.5 million, with a median of $113.9 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents plummeted 94.7% in 2022, then soared 2502.82% in 2024.
  • Year by year, Cash & Equivalents stood at $24.4 million in 2021, then skyrocketed by 334.3% to $105.8 million in 2022, then rose by 15.28% to $122.0 million in 2023, then soared by 94.48% to $237.2 million in 2024, then tumbled by 91.59% to $19.9 million in 2025.
  • Business Quant data shows Cash & Equivalents for RXST at $19.9 million in Q4 2025, $40.4 million in Q2 2025, and $229.3 million in Q1 2025.